[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR9809951A - Método para tratamento da obesidade - Google Patents

Método para tratamento da obesidade

Info

Publication number
BR9809951A
BR9809951A BR9809951-5A BR9809951A BR9809951A BR 9809951 A BR9809951 A BR 9809951A BR 9809951 A BR9809951 A BR 9809951A BR 9809951 A BR9809951 A BR 9809951A
Authority
BR
Brazil
Prior art keywords
treating obesity
amylin
methods
effective amount
therapeutically effective
Prior art date
Application number
BR9809951-5A
Other languages
English (en)
Inventor
Bradford J Duft
Orville Terman
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Publication of BR9809951A publication Critical patent/BR9809951A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção:<B>"MéTODO PARA TRATAMENTO DA OBESIDADE"<D>. Métodos para tratar obesidade são descritos, os quais compreendem a administração de uma quantidade terapeuticamente eficaz de uma amilina ou agonista de amilina sozinho ou em conjunto com outro agente de alívio de obesidade. Adicionalmente, são descritos métodos para reduzir o ganho de peso induzido por insulina, os quais compreendem a administração de uma quantidade terapeuticamente eficaz de uma amilina ou agonista de amilina.
BR9809951-5A 1997-06-06 1998-06-05 Método para tratamento da obesidade BR9809951A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/870,762 US7910548B2 (en) 1997-06-06 1997-06-06 Methods for treating obesity
PCT/US1998/011753 WO1998055144A1 (en) 1997-06-06 1998-06-05 Methods for treating obesity

Publications (1)

Publication Number Publication Date
BR9809951A true BR9809951A (pt) 2000-08-01

Family

ID=25356022

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809951-5A BR9809951A (pt) 1997-06-06 1998-06-05 Método para tratamento da obesidade

Country Status (10)

Country Link
US (1) US7910548B2 (pt)
AU (1) AU7823098A (pt)
BR (1) BR9809951A (pt)
CZ (1) CZ294983B6 (pt)
HU (1) HUP0004271A3 (pt)
NO (1) NO324818B1 (pt)
NZ (1) NZ501451A (pt)
PL (1) PL193236B1 (pt)
RU (2) RU2207871C2 (pt)
WO (1) WO1998055144A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2247676T3 (es) * 1997-01-07 2006-03-01 Amylin Pharmaceuticals, Inc. Uso de las exendinas y de los agonistas de las mismas para la reduccion de la ingesta alimenticia.
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US20040022807A1 (en) * 1998-06-05 2004-02-05 Duft Bradford J Methods for treating obesity
JP4353544B2 (ja) * 1998-01-09 2009-10-28 アミリン・ファーマシューティカルズ，インコーポレイテッド アミリン作動薬ペプチド用製剤
ES2316757T3 (es) * 2002-01-08 2009-04-16 Amylin Pharmaceuticals, Inc. Uso de agonistas de amilina para modular trigliceridos.
WO2005021026A2 (en) * 2003-08-29 2005-03-10 Amylin Pharmaceuticals, Inc. Methods for treating or ameliorating ghrelin-associated diseases and disorders
KR20120034237A (ko) 2004-02-11 2012-04-10 아밀린 파마슈티칼스, 인크. 선택가능한 특성을 갖는 하이브리드 폴리펩티드
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
DK1814590T4 (da) † 2004-11-01 2014-02-24 Amylin Pharmaceuticals Llc Behandling af obesitet og beslægtede sygdomme.
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
US20090286723A1 (en) * 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
EP2390264A1 (en) 2005-02-11 2011-11-30 Amylin Pharmaceuticals Inc. GIP analog and hybrid polypeptides with selectable propperties
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
WO2009003666A1 (en) * 2007-06-29 2009-01-08 Lonza Ag Process for the production of pramlintide
US8748375B2 (en) 2009-03-17 2014-06-10 Amylin Pharmaceuticals, Llc Methods for affecting body composition using amylin agonists
US20120071401A1 (en) * 2009-04-10 2012-03-22 Amylin Pharamaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
RU2552221C2 (ru) * 2010-07-15 2015-06-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ лечения ожирения и сопутствующих метаболических расстройств и лекарственное средство для лечения ожирения и сопутствующих метаболических расстройств
US8575091B1 (en) 2012-04-19 2013-11-05 Novo Nordisk A/S Amylin analogues and pharmaceutical compositions thereof
RU2523558C2 (ru) * 2012-08-22 2014-07-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Россиской Федерации Способ лечения и повышения качества жизни больных с синдромом диспепсии в сочетании с ожирением
WO2016146739A1 (en) 2015-03-18 2016-09-22 Zealand Pharma A/S Amylin analogues
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
US20230093542A1 (en) 2020-02-18 2023-03-23 Novo Nordisk A/S Glp-1 compositions and uses thereof
CA3175810A1 (en) * 2020-04-20 2021-10-28 Andrew Young Use of human amylin analog polypeptides for providing superior glycemic control to type 1 diabetics

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443619A (en) * 1978-12-26 1984-04-17 Hoffmann-La Roche Inc. Chlorocitric acids
US5367052A (en) 1987-04-27 1994-11-22 Amylin Pharmaceuticals, Inc. Amylin peptides
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US5364841A (en) 1988-01-11 1994-11-15 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
US5280014A (en) * 1988-01-11 1994-01-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
US5266561A (en) 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
IT1219667B (it) * 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
US5175145A (en) 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
ES2080802T3 (es) * 1989-07-10 1996-02-16 Amylin Pharmaceuticals Inc Uso de un antagonista de amilina en la preparacion de un medicamento para el tratamiento de la obesidad e hipertension intrinseca y desordenes asociados.
WO1991012799A1 (en) * 1990-02-28 1991-09-05 The Upjohn Company Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
WO1991016917A1 (en) * 1990-05-02 1991-11-14 The Upjohn Company Method of treating gastric ulcers and obesity
SE9003713L (sv) * 1990-11-22 1992-01-07 Kabi Pharmacia Ab Gelbildande flytande dietfiberkomposition
US5187154A (en) * 1990-12-13 1993-02-16 Board Of Regents, The University Of Texas System Diagnosis and treatment of humans with diabetes or at risk to develop diabetes
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5264372A (en) 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
WO1993010146A1 (en) 1991-11-19 1993-05-27 Amylin Pharmaceuticals, Inc. Amylin agonist peptides and uses therefor
WO1992015317A1 (en) 1991-03-08 1992-09-17 Amylin Pharmaceuticals, Inc. Synthetic preparation of amylin and amylin analogues
CA2109794A1 (en) 1991-05-24 1992-11-26 Timothy J. Rink Amylin and possibly insulin containing composition for the treatment of anorexia and related states
ES2101866T3 (es) * 1991-08-26 1997-07-16 Upjohn Co Producto alimentario liquido que contiene acido 3-guanidinopropionico.
DE69317877T2 (de) * 1992-01-21 1998-10-29 Abbott Lab 4''-deoxyerythromycinderivate
US5376638A (en) 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
HUT70176A (en) * 1993-05-12 1995-09-28 Univ Cincinnati Amylin antagonists and agonists
CN1134110A (zh) * 1993-09-07 1996-10-23 安米林药品公司 调节胃肠动力的方法
US5527788A (en) * 1994-01-18 1996-06-18 Louisiana State Univ. Medical Center Foundation Method and composition for treating obesity comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent
BR9507381A (pt) * 1994-04-14 1997-09-23 Glaxo Wellcome Inc Composto uso de um composto processo para o tratamento de um manifero composição famacèutica e processo para a preparação de compostos
US5739129A (en) * 1994-04-14 1998-04-14 Glaxo Wellcome Inc. CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
US5498424A (en) * 1994-11-30 1996-03-12 Klein; Ira Method of treating obesity
TW448046B (en) * 1995-01-20 2001-08-01 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity
US5766851A (en) * 1995-05-19 1998-06-16 The Johns Hopkins University School Of Medicine Susceptibility gene for obesity and type II diabetes mellitus
US6187991B1 (en) * 1995-05-23 2001-02-13 Pfizer Inc Transgenic animal models for type II diabetes mellitus
US5739106A (en) 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US5646040A (en) * 1995-06-30 1997-07-08 Millennium Pharmaceutical, Inc. Mammalian tub gene
US5972621A (en) * 1995-11-27 1999-10-26 Millennium Pharmaceuticals, Inc. Methods of identifying compounds that modulate body weight using the OB receptor
US6110707A (en) * 1996-01-19 2000-08-29 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
US5690691A (en) * 1996-05-08 1997-11-25 The Center For Innovative Technology Gastro-intestinal pacemaker having phased multi-point stimulation
US5932779A (en) * 1996-06-10 1999-08-03 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
US5965607A (en) * 1996-12-30 1999-10-12 American Home Products Corporation Substituted Benzo[1,4]dioxines as antiobesity agents
ES2247676T3 (es) * 1997-01-07 2006-03-01 Amylin Pharmaceuticals, Inc. Uso de las exendinas y de los agonistas de las mismas para la reduccion de la ingesta alimenticia.
US5830434A (en) * 1997-02-26 1998-11-03 Medical University Of South Carolina Foundation For Research Development Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide
US5955443A (en) * 1998-03-19 1999-09-21 Isis Pharmaceuticals Inc. Antisense modulation of PECAM-1
US6100047A (en) * 1999-04-07 2000-08-08 Zen Bio, Inc. Modulation of the sulfonylurea receptor and calcium in adipocytes for treatment of obesity/diabetes
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition

Also Published As

Publication number Publication date
CZ9904360A3 (cs) 2000-10-11
PL338082A1 (en) 2000-09-25
US7910548B2 (en) 2011-03-22
HUP0004271A2 (hu) 2001-05-28
AU7823098A (en) 1998-12-21
HUP0004271A3 (en) 2001-08-28
RU2207871C2 (ru) 2003-07-10
RU2314121C2 (ru) 2008-01-10
WO1998055144A1 (en) 1998-12-10
NO995996L (no) 2000-02-07
CZ294983B6 (cs) 2005-04-13
PL193236B1 (pl) 2007-01-31
RU2314121C9 (ru) 2008-08-10
NO995996D0 (no) 1999-12-06
NZ501451A (en) 2001-10-26
US20030026812A1 (en) 2003-02-06
NO324818B1 (no) 2007-12-10

Similar Documents

Publication Publication Date Title
BR9809951A (pt) Método para tratamento da obesidade
BR9811556A (pt) Terapia de combinação compreendendo atorvastatina e um agente anti-hipertensivo
CL2010000828A1 (es) Composicion farmaceutica que comprende un conjugado pegilado de interferon alfa y ribavirina, util en la preparacion de un medicamento para las infecciones de hepatitis c cronica.
BR9910180A (pt) Composição farmacêutica, processos para o tratamento de uma condição associada com a transmissão reduzida de nicotina, para identificação de um modulador positivo de um agonista receptor nicotìnico e para identificação de um composto, composto, e, uso de um modulador positivo de um agonista receptor nicotìnico
BRPI0410260A (pt) composição conjugada para medicamento
BR9813154A (pt) Compósitos de fibra celulósica
BR0311939A (pt) composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánico
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BR0007487A (pt) Difenil-uréias substituìdas com w-carbóxi-arilas como inibidores de raf cinase
BR0014003A (pt) Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra
BR9803168A (pt) Tratamento de parada cardìaca congestiva.
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
SE9300581D0 (sv) Komposition foer nasalbehandling
BR9914631A (pt) Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades
BR9807112A (pt) Composição, formulação farmacêutica, combinação e uso relacionados ao tratamento de doenças autoimunes utilizando antìgeno ou agente tolerante em combinação com metotrexato
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
AU7284098A (en) Method for preventing gastritis using amylin or amylin agonists
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
SE9603725D0 (sv) New teatment
CO5570661A2 (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina
BR0010546A (pt) Terapia antiinflamatória para infecção mediada inflamatória
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13, 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.